Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5217790 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15. |
| RO5217790 | EXPERIMENTAL | RO5217790 will be administered at a dose of 5\*10\^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15. |
| RO5217790 | DRUG | RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15. |
Inclusion Criteria: * Have a diagnosis within 2 months prior to the first dose of RO5217790 of CIN 2/3 confirmed by colposcopy-directed punch biopsy; patients must have at least 1 quadrant of residual CIN2/3 disease remaining after biopsy. Entry to the trial will be allowed based on the local asses...
RO5217790 is an investigational small molecule being studied for the treatment of high grade cervical intraepithelial neoplasia (CIN) associated with high risk human papillomavirus (HR-HPV) infection. It is being developed by Roche Holding AG (RHHBY) and is currently in Phase 2 clinical development.
The molecular target of RO5217790 has not been disclosed. It is a small molecule being evaluated for its potential to treat cervical intraepithelial neoplasia, a precancerous condition of the cervix associated with high risk human papillomavirus infection.
RO5217790 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational small molecule for the treatment of cervical intraepithelial neoplasia.
RO5217790 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed, with no active trials currently ongoing.
RO5217790 has been studied in one completed Phase 2 clinical trial, NCT01022346. This randomized, double-blind, placebo-controlled study enrolled 206 female participants with high grade cervical intraepithelial neoplasia associated with high risk human papillomavirus infection.
No alternative names for RO5217790 have been disclosed. The drug is identified solely by its development code RO5217790 in clinical trial records and is being studied for cervical intraepithelial neoplasia.